TrialScientific reports2025

Decision-making and acceptability of subcutaneously administered broadly neutralising monoclonal antibodies for HIV prevention amongst CAPRISA 012A trial participants in Durban, South Africa.

Hilton Humphries et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.